For hundreds of children born with thalassemia, life has long been measured in blood transfusions and iron overload. But a quiet medical revolution is unfolding, one transplant at a time. On September 4, 2026, a coalition of health organizations marked a breathtaking milestone: 1,000 pediatric stem cell transplants completed, offering not just treatment, but a cure.

Key facts

  • 1,000 stem cell transplants completed for children with thalassemia
  • Treatment cost in India ranges from ₹12 lakh to ₹40 lakh
  • DKMS supported transplantation costs for over 820 children
  • Sankalp provides care to more than 3,000 children through 30 day-care centres

A Family's Courageous Choice

Seventeen-year-old Muhammad Shaheem's story embodies both the struggle and the hope. Diagnosed at just five months old, his childhood revolved around regular blood transfusions. But years of treatment led to severe iron overload, damaging his heart and liver and making a transplant dangerously risky.

The turning point came from within his own family. His seven-year-old sister, Zara, was identified as a perfect HLA-matched donor. After extensive preparation at Bengaluru's Sankalp-Bhagwan Mahavir Jain Hospital, the family moved forward—gambling on a chance for a normal life.

“I continue to undergo treatment and regular blood transfusions. Though it was a difficult decision to make in my son’s case, it has ultimately given my son a second chance for better life without being troubled much by the disease,” said Zareena, Shaheem’s mother, who herself lives with thalassemia major.

The Power of Partnership

This milestone wasn’t achieved alone. Sankalp India Foundation joined forces with international nonprofit DKMS and medical partner Cure2Children Foundation, combining resources, expertise, and unwavering commitment.

Rajat Kumar Agarwal, president of Sankalp, struck a tone of quiet triumph. “For us, these 1,000 transplants are 1,000 beginnings and proof that cure can be made accessible when organisations combine their strengths with a shared purpose,” he said. His words reflect a broader truth: even in resource-constrained settings, medical excellence is achievable.

Behind the numbers are expanded care networks. Sankalp now operates pediatric bone marrow transplant centres in Bengaluru and Ahmedabad and supports over 3,000 children through a network of thalassemia day-care centres. Each centre represents another thread in a safety net that continues to grow.